RUNX3 is a Novel Negative Regulator of Oncogenic TEAD-YAP Complex in Gastric Cancer

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2015 Sep 15

PMID 26364597

Citations 51

Authors

Y Qiao

S J Lin

Y Chen

D C-C Voon

F Zhu

L S H Chuang

T Wang

P Tan

S C Lee

K G Yeoh

M Sudol

Y Ito

Affiliations

Soon will be listed here.

Abstract

Runt-related transcription factor 3 (RUNX3) is a well-documented tumour suppressor that is frequently inactivated in gastric cancer. Here, we define a novel mechanism by which RUNX3 exerts its tumour suppressor activity involving the TEAD-YAP complex, a potent positive regulator of proliferative genes. We report that the TEAD-YAP complex is not only frequently hyperactivated in liver and breast cancer, but also confers a strong oncogenic activity in gastric epithelial cells. The increased expression of TEAD-YAP in tumour tissues significantly correlates with poorer overall survival of gastric cancer patients. Strikingly, RUNX3 physically interacts with the N-terminal region of TEAD through its Runt domain. This interaction markedly reduces the DNA-binding ability of TEAD that attenuates the downstream signalling of TEAD-YAP complex. Mutation of RUNX3 at Arginine 122 to Cysteine, which was previously identified in gastric cancer, impairs the interaction between RUNX3 and TEAD. Our data reveal that RUNX3 acts as a tumour suppressor by negatively regulating the TEAD-YAP oncogenic complex in gastric carcinogenesis.

Citing Articles

TEAD switches interacting partners along neural progenitor lineage progression to execute distinct functions.

Perry C, Lavado A, Thulabandu V, Ramirez C, Pare J, Dixit R bioRxiv. 2025; .

PMID: 39868115 PMC: 11760702. DOI: 10.1101/2024.12.19.629472.

TLK1>Nek1 Axis Promotes Nuclear Retention and Activation of YAP with Implications for Castration-Resistant Prostate Cancer.

Olatunde D, De Benedetti A Cancers (Basel). 2024; 16(16).

PMID: 39199688 PMC: 11352418. DOI: 10.3390/cancers16162918.

YAP inhibition overcomes adaptive resistance in HER2-positive gastric cancer treated with trastuzumab via the AKT/mTOR and ERK/mTOR axis.

Qiao J, Feng M, Zhou W, Tan Y, Yang S, Liu Q Gastric Cancer. 2024; 27(4):785-801.

PMID: 38782859 PMC: 11193831. DOI: 10.1007/s10120-024-01508-3.

YAP1-CPNE3 positive feedback pathway promotes gastric cancer cell progression.

Li X, Zhong H, Shi Q, Ruan R, Huang C, Wen Q Cell Mol Life Sci. 2024; 81(1):143.

PMID: 38493426 PMC: 10944813. DOI: 10.1007/s00018-024-05178-3.

RUNX transcription factors: biological functions and implications in cancer.

Chen X, Wang L, Yang M, Zhao W, Tu J, Liu B Clin Exp Med. 2024; 24(1):50.

PMID: 38430423 PMC: 10908630. DOI: 10.1007/s10238-023-01281-0.

References

Min B, Kim M, Zhang J, Kim J, Chung K, Oh B . Identification of RUNX3 as a component of the MST/Hpo signaling pathway. J Cell Physiol. 2011; 227(2):839-49. PMC: 3632350. DOI: 10.1002/jcp.22887. View

Cinghu S, Goh Y, Oh B, Lee Y, Lee O, Devaraj H . Phosphorylation of the gastric tumor suppressor RUNX3 following H. pylori infection results in its localization to the cytoplasm. J Cell Physiol. 2011; 227(3):1071-80. DOI: 10.1002/jcp.22820. View

Voon D, Wang H, Koo J, Nguyen T, Hor Y, Chu Y . Runx3 protects gastric epithelial cells against epithelial-mesenchymal transition-induced cellular plasticity and tumorigenicity. Stem Cells. 2012; 30(10):2088-99. DOI: 10.1002/stem.1183. View

Fukumoto Y, Kurita S, Takai Y, Ogita H . Role of scaffold protein afadin dilute domain-interacting protein (ADIP) in platelet-derived growth factor-induced cell movement by activating Rac protein through Vav2 protein. J Biol Chem. 2011; 286(50):43537-48. PMC: 3234878. DOI: 10.1074/jbc.M111.308858. View

Lochhead P, El-Omar E . Gastric cancer. Br Med Bull. 2008; 85:87-100. DOI: 10.1093/bmb/ldn007. View

Lee Y, Lee J, Jang J, Chi X, Kim J, Li Y . Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma. Cancer Cell. 2013; 24(5):603-16. DOI: 10.1016/j.ccr.2013.10.003. View

Chakraborty P, Zhang Y, Coomes A, Kim W, Stupay R, Lynch L . G protein-coupled receptor kinase GRK5 phosphorylates moesin and regulates metastasis in prostate cancer. Cancer Res. 2014; 74(13):3489-500. DOI: 10.1158/0008-5472.CAN-13-2708. View

Shah M, Ajani J . Gastric cancer--an enigmatic and heterogeneous disease. JAMA. 2010; 303(17):1753-4. DOI: 10.1001/jama.2010.553. View

Karagiannis G, Petraki C, Prassas I, Saraon P, Musrap N, Dimitromanolakis A . Proteomic signatures of the desmoplastic invasion front reveal collagen type XII as a marker of myofibroblastic differentiation during colorectal cancer metastasis. Oncotarget. 2012; 3(3):267-85. PMC: 3359884. DOI: 10.18632/oncotarget.451. View

10.

Yamada C, Ozaki T, Ando K, Suenaga Y, Inoue K, Ito Y . RUNX3 modulates DNA damage-mediated phosphorylation of tumor suppressor p53 at Ser-15 and acts as a co-activator for p53. J Biol Chem. 2010; 285(22):16693-703. PMC: 2878082. DOI: 10.1074/jbc.M109.055525. View

11.

Lin Y, Ding J, Li M, Yeh T, Wang T, Yu J . YAP regulates neuronal differentiation through Sonic hedgehog signaling pathway. Exp Cell Res. 2012; 318(15):1877-88. DOI: 10.1016/j.yexcr.2012.05.005. View

12.

Lai D, Ho K, Hao Y, Yang X . Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res. 2011; 71(7):2728-38. DOI: 10.1158/0008-5472.CAN-10-2711. View

13.

Liu-Chittenden Y, Huang B, Shim J, Chen Q, Lee S, Anders R . Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012; 26(12):1300-5. PMC: 3387657. DOI: 10.1101/gad.192856.112. View

14.

Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S . YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response. Cell. 2014; 158(1):157-70. DOI: 10.1016/j.cell.2014.06.013. View

15.

Jiang C, Lv L, Liu F, Wang Z, Liu F, Li Y . Downregulation of connective tissue growth factor inhibits the growth and invasion of gastric cancer cells and attenuates peritoneal dissemination. Mol Cancer. 2011; 10:122. PMC: 3192775. DOI: 10.1186/1476-4598-10-122. View

16.

Sudol M . Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene. 1994; 9(8):2145-52. View

17.

Bork P, Sudol M . The WW domain: a signalling site in dystrophin?. Trends Biochem Sci. 1994; 19(12):531-3. DOI: 10.1016/0968-0004(94)90053-1. View

18.

Varelas X, Samavarchi-Tehrani P, Narimatsu M, Weiss A, Cockburn K, Larsen B . The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-β-SMAD pathway. Dev Cell. 2010; 19(6):831-44. DOI: 10.1016/j.devcel.2010.11.012. View

19.

Zhao B, Li L, Lu Q, Wang L, Liu C, Lei Q . Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev. 2011; 25(1):51-63. PMC: 3012936. DOI: 10.1101/gad.2000111. View

20.

Fan X, Hu X, Han T, Wang N, Zhu Y, Hu W . Association between RUNX3 promoter methylation and gastric cancer: a meta-analysis. BMC Gastroenterol. 2011; 11:92. PMC: 3183003. DOI: 10.1186/1471-230X-11-92. View